A Phase 4 interventional study of Fingolimod (FTY720) in Relapsing Remitting Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 47 sites in 2 countries. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2019-01-25.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. fingolimod · Multiple Sclerosis, Relapsing-Remitting.
Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, this one is the 6th largest by enrollment, is one of 6 that started in 2011, is one of 14 in phase 4, and was the 8th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 6 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 347 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 142 across the 19 interventional studies. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 19 have an industry lead sponsor. The 5 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis: 1 open now, 4 under way, none of them phase 3. Of 28 finished, 19 (68%) have results posted.
Among the 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis, this one is the 6th largest by enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2011, is one of 15 in phase 4, and was the 12th registered.
Novartis’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Among Novartis’s 34 in Multiple Sclerosis, Relapsing-Remitting:
This tab as a report to print or save as PDF → With an account.
This study assessed the efficacy of fingolimod in patients with short duration relapsing-remitting multiple sclerosis who had not been previously treated with disease-modifying therapies (DMTs), versus patients with the same disease duration who had previously received first-line DMTs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients
Exclusion Criteria:
Fingolimod at any time (e.g. participation in a fingolimod clinical trial), drugs such as azathioprine or methotrexate at any time; Immunoglobulins in the past 6 months. Monoclonal antibodies including natalizumab, Cladribine, cyclophosphamide or mitoxantrone, at any time.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 0.5 mg FTY720 (fingolimod) orally once daily for 12 months.
Drug: Fingolimod (FTY720)
Participants received 0.5 mg FTY720 (fingolimod) orally once daily for 12 months.
Drug: Fingolimod (FTY720)
Hard gelatin capsules containing 0.5 mg of fingolimod.
Annual Relapse Rate (ARR)
ARR = 365 days \* number of relapses / total days taking the study medication.
Time frame: 12 months
Time to First Relapse
Time to first relapse was defined as the time from the first day of treatment to the first day of a new neurological symptom or worsening of an existing one.
Time frame: first day of treatment to the first day of a new neurological symptom or worsening of an existing one, up to 12 months
Change From Baseline in Expanded Disability Status Scale (EDSS) Score
The EDSS is an ordinal clinical rating scale ranging from a total score of 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments. A negative change from baseline indicates improvement.
Time frame: baseline, 12 months
Change From Baseline in Cerebral Volume
Cerebral volume was assessed by magnetic resonance imaging (MRI). A negative change from baseline indicates improvement.
Time frame: baseline, 12 months
Percentage of Participants With Mild, Moderate or Severe Relapse
The investigator classified a relapse as moderate-severe if oral or intravenous (IV) treatment (according to the local clinical practice) with steroids and/or hospitalization was needed. If neither oral nor IV treatment with steroids nor hospitalization was needed, the relapse was considered as mild.
Time frame: 12 months
Percentage of Relapse-free Participants
Relapse-free participants were defined as participants who experienced no new neurological symptom or worsening of an existing one (relapses) during the 12-month treatment period with 0.5 mg fingolimod.
Time frame: 12 months
Mean Number of T2 Active Lesions
The mean number of new or enlarged T2 active lesions was assessed by MRI.
Time frame: 12 months
| Milestone | Naive or de Novo Participants | Previously Treated With First-line DMTs Participants |
|---|---|---|
| Started | 200 | 147 |
| Safety set | 200 | 147 |
| Intent-to-treat | 185 | 135 |
| Completed | 184 | 136 |
| Not completed | 16 | 11 |
| Withdrew: Administrative problems | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Protocol violation | 1 | 3 |
| Withdrew: Lack of efficacy | 5 | 3 |
| Withdrew: Abnormal result from test procedure | 1 | 1 |
| Withdrew: Abnormal laboratory value | 2 | 2 |
| Withdrew: Adverse event | 4 | 1 |
ARR = 365 days \* number of relapses / total days taking the study medication.
| Relapses per year | Naive or de Novo Participants | Previously Treated With First-line DMTs Participants |
|---|---|---|
| Annual Relapse Rate (ARR) | 0.290 ± 0.7399 | 0.354 ± 0.8547 |
Time to first relapse was defined as the time from the first day of treatment to the first day of a new neurological symptom or worsening of an existing one.
| months | Naive or de Novo Participants | Previously Treated With First-line DMTs Participants |
|---|---|---|
| Time to First Relapse | NA (NA to NA) | NA (NA to NA) |
The EDSS is an ordinal clinical rating scale ranging from a total score of 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments. A negative change from baseline indicates improvement.
| score on a scale | Naive or de Novo Participants | Previously Treated With First-line DMTs Participants |
|---|---|---|
| Change From Baseline in Expanded Disability Status Scale (EDSS) Score | 0.000 ± 0.8040 | -0.077 ± 0.7911 |
Cerebral volume was assessed by magnetic resonance imaging (MRI). A negative change from baseline indicates improvement.
| Percent change | Naive or de Novo Participants | Previously Treated With First-line DMTs Participants |
|---|---|---|
| Change From Baseline in Cerebral Volume | -0.595 (-0.759 to -0.431) | -0.387 (-0.583 to -0.191) |
The investigator classified a relapse as moderate-severe if oral or intravenous (IV) treatment (according to the local clinical practice) with steroids and/or hospitalization was needed. If neither oral nor IV treatment with steroids nor hospitalization was needed, the relapse was considered as mild.
| Percentage of participants | Naive or de Novo Participants | Previously Treated With First-line DMTs Participants |
|---|---|---|
| Mild | 42.55 | 38.46 |
| Moderate | 57.45 | 56.41 |
| Severe | 0.00 | 5.13 |
Relapse-free participants were defined as participants who experienced no new neurological symptom or worsening of an existing one (relapses) during the 12-month treatment period with 0.5 mg fingolimod.
| Percent | Naive or de Novo Participants | Previously Treated With First-line DMTs Participants |
|---|---|---|
| Percentage of Relapse-free Participants | 71.89 | 66.67 |
The mean number of new or enlarged T2 active lesions was assessed by MRI.
| T2 lesions | Naive or de Novo Participants | Previously Treated With First-line DMTs Participants |
|---|---|---|
| Mean Number of T2 Active Lesions | 2.0 ± 3.36 | 1.6 ± 2.72 |
Collected over Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit, approximately 4 years.. Non-serious events are listed at a 0.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Naive or de Novo Participants | — | 11/200 (5.5%) | 143/200 (71.5%) |
| Previously Treated With First-line DMTs Participants | — | 4/147 (2.7%) | 114/147 (77.6%) |
| All Participants | — | 15/347 (4.3%) | 257/347 (74.1%) |
| Event | Naive or de Novo Participants | Previously Treated With First-line DMTs Participants | All Participants |
|---|---|---|---|
| Sinus bradycardiaCardiac disorders | 2/200 | 0/147 | 2/347 |
| CholelithiasisHepatobiliary disorders | 2/200 | 0/147 | 2/347 |
| Multiple sclerosis relapseNervous system disorders | 2/200 | 1/147 | 3/347 |
| BradycardiaCardiac disorders | 0/200 | 1/147 | 1/347 |
| Drug hypersensitivityImmune system disorders | 0/200 | 1/147 | 1/347 |
| Lower respiratory tract infectionInfections and infestations | 0/200 | 1/147 | 1/347 |
| Atrioventricular blockCardiac disorders | 1/200 | 0/147 | 1/347 |
| Atrioventricular block second degreeCardiac disorders | 1/200 | 0/147 | 1/347 |
| Hepatitis acuteHepatobiliary disorders | 1/200 | 0/147 | 1/347 |
| Diffuse large B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/200 | 0/147 | 1/347 |
| Event | Naive or de Novo Participants | Previously Treated With First-line DMTs Participants | All Participants |
|---|---|---|---|
| HeadacheNervous system disorders | 17/200 | 17/147 | 34/347 |
| Urinary tract infectionInfections and infestations | 15/200 | 15/147 | 30/347 |
| Upper respiratory tract infectionInfections and infestations | 15/200 | 12/147 | 27/347 |
| NasopharyngitisInfections and infestations | 16/200 | 8/147 | 24/347 |
| DiarrhoeaGastrointestinal disorders | 5/200 | 9/147 | 14/347 |
| FatigueGeneral disorders | 11/200 | 9/147 | 20/347 |
| Back painMusculoskeletal and connective tissue disorders | 12/200 | 4/147 | 16/347 |
| AnxietyPsychiatric disorders | 11/200 | 6/147 | 17/347 |
| LymphopeniaBlood and lymphatic system disorders | 9/200 | 7/147 | 16/347 |
| DizzinessNervous system disorders | 5/200 | 7/147 | 12/347 |
The analysis of the baseline characteristics was done on the ITT population
| Age, Continuous(Years) | Naive or de Novo Participants | Previously Treated With First-line DMTs Participants | Total |
|---|---|---|---|
| Mean | 33.1 ± 8.08 | 34.0 ± 7.44 | 33.5 ± 7.81 |
| Sex: Female, Male(Participants) | Naive or de Novo Participants | Previously Treated With First-line DMTs Participants | Total |
|---|---|---|---|
| Female | 137 | 88 | 225 |
| Male | 48 | 47 | 95 |
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2011 to primary completion in Dec 2015, 48 months.
Results were first posted in Jan 2019, 3 years after primary completion.
Of 28 phase 4 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's 48 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod
Multiple Sclerosis, Relapsing-Remitting →